The shares of this international pharmaceutical firm surged by roughly 5 p.c after the corporate introduced strong monetary efficiency throughout this monetary yr. On this article, we’ll take a look at the small print.
With a market capitalisation of 15,042 crores, the shares of Jubilant Pharmova Ltd are presently buying and selling at Rs 944 per share, down by 28 p.c from its 52-week excessive of Rs 1,309.90 per share. Within the final one yr, the inventory has delivered a return of 33.05 p.c.
Monetary Highlights
Jubilant Pharmova reported a consolidated income of Rs 7,234.5 crores in FY25, up 7.94 p.c from Rs 6,702.9 crores in FY24. Moreover, on a year-on-year foundation, income grew 9.68 p.c to Rs 1,928.8 crores in This fall FY25 from Rs 1,758.6 crores in This fall FY24. On a quarterly foundation, income elevated by 5.88 p.c from Rs 1,821.7 crores.
It reported a internet revenue of Rs 836.3 crores in FY25, up 1,050.07 p.c from Rs 72.7 crores in FY24. Moreover, it rotated to a internet revenue of Rs 151.3 crores in This fall FY25 as in comparison with a lack of Rs 61.8 crores in This fall FY24. On a quarterly foundation, internet revenue grew by 50.23 p.c from Rs 100.7 crores. Moreover, it beneficial a dividend of Rs 5 per share on a face worth of Rs 1 (500 p.c), topic to the approval by the board.
In FY25 income, the Radiopharma phase was the best contributor with Rs 3,388 crore, adopted by CDMO – Sterile Injectables with Rs 1,272 crore, CRDMO with Rs 1,151 crore, Allergy Immunotherapy with Rs 701 crore, and Generics with Rs 685 crore. The Proprietary Novel Medication phase didn’t contribute to the topline within the yr.
In regards to the firm
Jubilant Pharmova Restricted is a vertically built-in pharmaceutical agency with companies in India, the Americas, Europe, and worldwide. It has companies in six verticals, particularly Radiopharma for analysis and remedy of illnesses, Allergy Immunotherapy, Sterile Injectables CDMO, Generics, CRDMO (contract analysis and manufacturing), and Proprietary Novel Medication with a concentrate on oncology and autoimmune remedy. It has shoppers in pharma, biotech, hospitals, and healthcare industries by way of a distribution channel that’s worldwide.
Written by Satyajeet Mukherjee
Disclaimer
The views and funding suggestions expressed by funding specialists/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Buyers should due to this fact train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the writer usually are not chargeable for any losses brought about because of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
